Jane N. Zuckerman|Caroline Sabin|Francesco Craig|A. Prysor Williams|Arie J. Zuckerman
Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study
The Royal Free Hospital|University College London|The Royal Free Hospital|University College London|The Royal Free Hospital|University College London
evaluate immunogenicity reactogenicity new triple recombinant hepatitis b vaccine cohort healthy people currently licensed hepatitis b vaccines persistently induced immune responsesingle centre randomised double blind doseresponse studyresearch vaccine evaluation centre teaching hospital100 healthcare workers aged 1870 years history failure seroconvert least four doses licensed hepatitis b vaccine containing componenteach subject randomly allocated two doses 5 10 20 40 micrograms new hepatitis b vaccine two months apartimmunogenicity four doses seroconversion seroprotection defined antibody tire 10 iul 100 iul respectively international antibody standard69 subjects seroconverted single dose vaccine booster vaccination one subject seroconverted bringing overall seroconversion rate 70 fifteen subjects given 5 micrograms vaccine 19 given 10 micrograms 16 given 20 micrograms 20 given 40 micrograms seroconverted seroconversion rates four antigen dose groups 60 1525 76 1925 64 1625 80 2025 booster dose significant doseresponse effect overall seroconversion rate although small sample size meant clinically important doseresponse could ruled outa single dose 20 micrograms vaccine effective two doses either 40 micrograms 20 micrograms vaccine formulation terms seroconversion seroprotection geometric mean titres